Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MRP1-Dependent Extracellular Release of Glutathione Induces Cardiomyocyte Ferroptosis After Ischemia-Reperfusion.
Ichihara G, Katsumata Y, Sugiura Y, Matsuoka Y, Maeda R, Endo J, Anzai A, Shirakawa K, Moriyama H, Kitakata H, Hiraide T, Goto S, Ko S, Iwasawa Y, Sugai K, Daigo K, Goto S, Sato K, Yamada KI, Suematsu M, Ieda M, Sano M. Ichihara G, et al. Among authors: goto s. Circ Res. 2023 Oct 27;133(10):861-876. doi: 10.1161/CIRCRESAHA.123.323517. Epub 2023 Oct 11. Circ Res. 2023. PMID: 37818671
Selection of a suitable patient population for new antiplatelet therapy from the large clinical trial database of the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-thrombolysis in myocardial infarction 50 (TRA-2P-TIMI50) trial.
Goto S, Goto S. Goto S, et al. Circulation. 2015 Mar 24;131(12):1041-3. doi: 10.1161/CIRCULATIONAHA.115.015471. Epub 2015 Feb 13. Circulation. 2015. PMID: 25681465 No abstract available.
Editorial Comment for the "Risk of Thrombocytopenia with Glycoprotein IIb/IIIa Inhibitors across Drugs and Patient Populations: a Meta-Analysis of 29 Large Placebo-Controlled Randomized Trials". Thrombocytopenia as an important complication with the use of antithrombotic agents.
Goto S, Goto S. Goto S, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Jan;1(1):29-30. doi: 10.1093/ehjcvp/pvu014. Epub 2015 Jan 1. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533961 No abstract available.
Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?
Goto S, Goto S. Goto S, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):83-5. doi: 10.1093/ehjcvp/pvu017. Epub 2015 Feb 19. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533975 No abstract available.
3,600 results